Fact sheet updated November 2018

Genmab

To improve the lives of patients by creating & developing innovative antibody products

2 marketed products

DARZALEX® marketed in the US, Europe, Japan & other countries
Arzerra® marketed globally[1]

3 proprietary technologies

DuoBody® bispecific platform
HexaBody® technology
HexElect™ technology

~20 pre-clinical projects

Extensive partnered & own pre-clinical pipeline incl. DuoBody-CD40x4-1BB

Solid financial base

Allows for building capabilities to market own product in future

4 proprietary clinical programs

Tisotumab vedotin, enapotamab vedotin (HuMax®-AXL-ADC), HexaBody-DR5/DR5, DuoBody-CD3xCD20

2 categories of cancer

Generate products to treat both solid tumors & hematological cancers

3 office locations

Facilities in Denmark, the Netherlands & USA

28 INDs

Investigational new drug applications filed by Genmab & partners in 18 years

DKK
63B
~USD 10M[2]
2017 year end market cap

DKK
1,021M
~USD 159M[2]
2017 operating expenses
34% increase versus 2016

DKK
2,365M
~USD 367[2]
2017 revenue
30% increase versus 2016

DKK
5,423M
~USD 842M[2]
2017 year end cash position

Operating Result
MDKK (~MUSD[2])



2018 Guidance

Income Statement	DKKM	USDM[2]
Revenue	2,700 – 3,100	419 - 482
Operating expenses	(1,400) – (1,600)	(217) – (249)
Operating income	1,300 – 1,500	202 - 233

[2]USD 1.00 = DKK 6.4377

Our Three-pronged Strategy
Focus on core competence
Turn science into medicine
Build a profitable & successful biotech

Our Vision
By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Executive Management:

Jan G. J. van de Winkel
Ph.D. President & CEO

David A. Eatwell FCCA
Executive Vice President & CFO

Judith Klimovsky M.D.
Executive Vice President & CDO

Founded: 1999, IPO: 2000
Exchange: NASDAQ
OMX Copenhagen A/S

Symbol:
GEN

ADR ticker Symbol:

GMXAY

Stock information as of November 14, 2018:

Market cap:
~DKK 57 Bn (~USD 8,572 M)

Shares outstanding:
61,489,983

[1]See Arzerra "At-A-Glance" on following page for additional information

For more information: genmab.com or contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications (rcg@genmab.com)

Robust Product Pipeline and Passion for Innovation

Development for Marketed & Genmab Proprietary Products

Product		Disease Indications	Development Phase: Pre-clinical	I	I/II	II	III
Daratumumab Target: CD38, Partner: Janssen	BTD (2 – MM)	Multiple myeloma (MM)					
		Amyloidosis					
		Non-MM blood cancers					
Ofatumumab (OMB157) Target: CD20, Partner: Novartis	BTD (CLL)	Relapsing multiple sclerosis (RMS) (SubQ)					
Tisotumab vedotin Target: TF, Partner: Seattle Genetics		Cervical cancer					
		Ovarian cancer					
		Solid tumors					
Enapotamab vedotin (HuMax-AXL-ADC) Target: AXL		Solid tumors					
HexaBody-DR5/DR5 Target: DR5		Solid tumors					
DuoBody-CD3xCD20 Targets: CD20, CD3		Hematological malignancies					
Additional Shots on Goal							
Teprotumumab (RV001) Target: IGF-1R, Partner: River Vision	BTD	Graves' orbitopathy					
HuMax-IL8 Target: IL8, Partner: BMS		Advanced cancers					
Camidanlumab tesirine (ADCT-301) Target: CD25, Partner: ADCT		Lymphoma					
		Solid tumors					
		AML or ALL					
JNJ-61186372 Targets: EGFR, cMET, Partner: Janssen		Non-small-cell lung cancer (NSCLC)					
JNJ-63709178[4] Targets: CD3, CD123, Partner: Janssen		AML					
JNJ-64007957 Targets: BCMA, CD3, Partner: Janssen		Relapsed or refractory MM					
JNJ-64407564 Targets: CD3,GPRC5D, Partner: Janssen		Relapsed or refractory MM					
Lu AF82422 Target: α-Synuclein, Partner: Lundbeck		Parkinson's Disease					
~20 Active Pre-clinical programs incl., DuoBody-CD40x4-1BB		Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody					
		Partnered programs: HuMab, DuoBody & HexaBody					

[4] As per clinicaltrials.gov, trial currently on hold due to Grade 3 event.

Products in development: Daratumumab, Ofatumumab, Tisotumab vedotin, HuMax-AXL-ADC, HexaBody-DR5/DR5, DuoBody-CD3xCD20, Pre-clinical programs, Technologies

At-A-Glance – SELECTED PRODUCTS

DARZALEX® (daratumumab)[3]

- First-in-class CD38 antibody in dev. to treat cancer
- Approvals:
  - US & EU, monotherapy for double refractory MM & in combo w/ Velcade®, melphalan & prednisone for newly diagnosed MM pts ineligible for ASCT
  - US, EU & Japan, in combo w/ Revlimid® & dex or Velcade® & dex for RRMM
  - US in combo w/ Pomalyst® & dex for pts w/ MM who have received at least 2 prior therapies
- Multiple Phase III studies ongoing in MM & amyloidosis
- Early stage studies ongoing in other indications
- Subcutaneous formulation in development
- Collaboration with Janssen
- 2017 net sales reported by Janssen; $1,242M

Tisotumab vedotin

- Antibody-drug conjugate (ADC, antibody coupled to a cell-killing agent) in dev. to treat solid tumors
- Ph II studies ongoing in cervical cancer & solid tumors
- 50:50 co-development with Seattle Genetics

Enapotamab vedotin (HuMax®-AXL-ADC)

- ADC in development to treat solid tumors
- Ph I/II clinical study for six types of solid tumors ongoing

DuoBody-CD3xCD20

- Proprietary bispecific antibody created with Genmab's DuoBody technology
- Phase I/II clinical trial in B-cell malignancies started

Arzerra® (ofatumumab)[3]

- Human CD20 antibody in dev. to treat cancer & autoimmune disease
- Approved in certain territories for certain CLL indications. On January 22, 2018 announced that Novartis intends to transition Arzerra from commercial availability to limited availability via compassionate use programs in non-US markets.
- 2 Ph III studies w/ low dose subcutaneous in relapsing multiple sclerosis fully recruited
- Collaboration with Novartis

HexaBody-DR5/DR5

- Proprietary antibody therapeutic created with Genmab's HexaBody technology
- Composed of two non-competing HexaBody molecules that target two distinct DR5 epitopes
- Phase I/II clinical trial in solid tumors started

Pre-Clinical Programs

- Broad pre-clinical pipeline of ~20 programs including DuoBody-CD40x4-1BB, DuoBody-PD-L1x4-1BB & DuoHExaBody-CD37
- Pre-clinical pipeline includes both partnered products & in-house programs based on our proprietary technologies
- Multiple INDs expected to be submitted over coming years

[3] See local country prescribing information for precise indications

TECHNOLOGIES

DuoBody® Platform

- Genmab's proprietary bispecific antibody tech.
- Generates bispecific antibodies that can bind to two targets or different epitopes on one target
- Potential application in cancer, autoimmune, infectious, cardiovascular, CNS diseases & hemophilia
- Multiple ongoing commercial & research collaborations

DuoHexaBody™ Technology

- Bispecific antibodies w/ target-mediated enhanced hexamerization
- Dual targeting + enhanced potency
- Combines DuoBody & HexaBody tech.

HexaBody® Technology

- Genmab's proprietary technology designed to increase the potency of antibodies
- Potential application in cancer and infectious diseases
- Broadly applicable tech. that builds on natural antibody biology

HexElect™ Technology

- Two co-dependent antibodies w/ target-mediated enhanced hexamerization
- Dual targeting + enhanced potency & selectivity
  - Co-dependent unlocking of potency
  - New target space, previously inaccessible